What To Know
- The Board and I are thrilled that she is joining us at such a pivotal time, as we work to continue the transformation of Inogen into a respiratory care MedTech leader, with durable performance and profitability.
- I look forward to working with the Board, Nabil and the rest of the management team to execute on the strategic plan and work to position the Company for sustainable, long-term growth.
Kristin Caltrider succeeds Mike Sergesketter, who joined the Company as interim CFO in December 2021, and will remain with Inogen through June 24, 2022 to facilitate a smooth transition.
Nabil Shabshab, President and Chief Executive Officer of Inogen, said, “Kristin Caltrider is a proven executive who brings deep experience in leading the financial operations of healthcare businesses. She has a clear track record of partnering cross functionally to successfully develop strategic plans and execute against a clear set of financial and business goals to add scale and drive profitable growth. The Board and I are thrilled that she is joining us at such a pivotal time, as we work to continue the transformation of Inogen into a respiratory care MedTech leader, with durable performance and profitability.”
Kristine Caltrider said, “Inogen is on a great trajectory and it’s an exciting time to join the Company. Inogen has a wealth of talent and a clear opportunity to build on its strong platform and drive value for patients and investors alike. I look forward to working with the Board, Nabil and the rest of the management team to execute on the strategic plan and work to position the Company for sustainable, long-term growth.”
Mr. Shabshab continued, “I want to thank Mike for his steady support during our search process for a CFO – I am grateful for his willingness to come out of retirement to support Inogen and for bringing his experience and discipline to bear which we have benefited from greatly.”
Ms. Caltrider joins Inogen from Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems listed on NASDAQ, where she most recently served as Vice President of Finance since June 2014.
In this role, Ms. Caltrider oversaw global Finance and Accounting functions, which included all aspects of transactional and technical accounting, tax and treasury, financial planning and analysis, cash management and forecasting, finance-related M&A activities as well as global analytics, and sales operations.
While in that role, she helped the company aggressively scale its manufacturing capacity and significantly expand revenue and profitability. Ms. Caltrider first joined Quidel in 2007, where she held roles of increasing responsibility. Prior to joining Quidel, Ms. Caltrider spent almost four years at Life Technologies (now Thermo Fisher), where she held a number of positions. Ms. Caltrider graduated from California Lutheran University with a bachelor’s degree in Business Administration, and also holds an MBA from the University of San Diego.
